Evidence map›Paper›PMID 23726004›Full record

ArticleInternational journal of radiation oncology, biology, physics2013

Molecular imaging of the ATM kinase activity.

Terence M Williams, Shyam Nyati, Brian D Ross, Alnawaz Rehemtulla

Open access · greenAbstract readValidation Study
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Imaging Proteolytic Activities in Mouse Models of Cancer.Methods in molecular biology (Clifton, N.J.) · 2018
    Article
  5. Imaging the DNA damage response with PET and SPECT.European journal of nuclear medicine and molecular imaging · 2017
    Review
  6. Article
  7. Quantitative and Dynamic Imaging of ATM Kinase Activity.Methods in molecular biology (Clifton, N.J.) · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Terence M WilliamsDepartment of Radiation Oncology, Ohio State University, Columbus, Ohio, USA.
Shyam Nyati
Brian D Ross
Alnawaz Rehemtulla
University of Michigan–Ann Arbor · USThe Ohio State University · US

Funding

Small Animal Imaging CoreP50CA093990 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2002 to 2012
$19.0M
Molecular Imaging of Phospho-FADD and its role in resistance to therapyR01CA129623 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REHEMTULLA, ALNAWAZ · 2007 to 2011
$1.4M
NCI NIH HHS P50 CA093990NCI NIH HHS P50CA093990NCI NIH HHS R01 CA129623NCI NIH HHS R01CA129623
6 · The paper itself

Abstract

purposeAtaxia telangiectasia mutated (ATM) is a serine/threonine kinase critical to the cellular DNA-damage response, including from DNA double-strand breaks. ATM activation results in the initiation of a complex cascade of events including DNA damage repair, cell cycle checkpoint control, and survival. We sought to create a bioluminescent reporter that dynamically and noninvasively measures ATM kinase activity in living cells and subjects. METHODS AND MATERIALS: Using the split luciferase technology, we constructed a hybrid cDNA, ATM-reporter (ATMR), coding for a protein that quantitatively reports on changes in ATM kinase activity through changes in bioluminescence.

resultsTreatment of ATMR-expressing cells with ATM inhibitors resulted in a dose-dependent increase in bioluminescence activity. In contrast, induction of ATM kinase activity upon irradiation resulted in a decrease in reporter activity that correlated with ATM and Chk2 activation by immunoblotting in a time-dependent fashion. Nuclear targeting improved ATMR sensitivity to both ATM inhibitors and radiation, whereas a mutant ATMR (lacking the target phosphorylation site) displayed a muted response. Treatment with ATM inhibitors and small interfering (si)RNA-targeted knockdown of ATM confirm the specificity of the reporter. Using reporter expressing xenografted tumors demonstrated the ability of ATMR to report in ATM activity in mouse models that correlated in a time-dependent fashion with changes in Chk2 activity.

conclusionsWe describe the development and validation of a novel, specific, noninvasive bioluminescent reporter that enables monitoring of ATM activity in real time, in vitro and in vivo. Potential applications of this reporter include the identification and development of novel ATM inhibitors or ATM-interacting partners through high-throughput screens and in vivo pharmacokinetic/pharmacodynamic studies of ATM inhibitors in preclinical models.

Indexed as

Genes, ReporterAnimalsAtaxia Telangiectasia Mutated ProteinsBenzeneacetamidesCaffeineCell Cycle ProteinsCell NucleusCheckpoint Kinase 2DNA-Binding ProteinsDNA, ComplementaryDNA PrimersDNA RepairDose-Response Relationship, DrugEnzyme ActivationFemaleHEK293 CellsAtaxia Telangiectasia Mutated ProteinsATM protein, humanAtm protein, mouseBenzeneacetamidesCaffeineCell Cycle ProteinsCGK 733Checkpoint Kinase 2CHEK2 protein, humanChek2 protein, mouseDNA-Binding ProteinsDNA, ComplementaryDNA PrimersLuciferasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesRNA, Small InterferingThioureaTumor Suppressor Proteins

Identifiers

PMID23726004
PMCPMC3710537
OpenAlexW2025753451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.